Advanced Solid Tumor Clinical Trial
— PROFILER 02Official title:
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Verified date | March 2022 |
Source | Centre Leon Berard |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The PROFILER 02 program is a multicenter, randomized, prospective cohort study aiming to compare the clinical relevance of a large Next-generation sequencing (NGS) panel (FondationOne or FOne panel) versus a limited NGS panel (CONTROL or CTL panel) in patients with advanced solid tumors. This study will allow adapting the therapeutic management of these patients, if needed, by giving them recommended therapies (commercialized or in ongoing clinical trials), based on the recommendations of the Molecular Tumor Board (MTB).
Status | Completed |
Enrollment | 341 |
Est. completion date | November 23, 2021 |
Est. primary completion date | November 23, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female patient aged = 18 years at time of inform consent signature. - Currently treated by a first or a second line of chemotherapy for their advanced cancer (local relapse or metastatic; Immunotherapies, Endocrine therapies and Targeted therapies are not considered as a line of chemotherapy). - Histologically confirmed diagnosis of advanced (local relapse or metastatic), incurable solid tumors from any histological types (except those listed in exclusion criteria 3). - I4. Availability of an adequate tumor sample to be sent imperatively to the CLB within 15 days after ICF signature by order of preference either (i1) a tumor archival FFPE block not older than 3 months prior to ICF signature or if not available :(ii2) a dedicated biopsy from one accessible lesion visible by medical imaging and accessible to percutaneous sampling with a diameter of at least 10 mm or if not feasible (3) an archival tumor sample (primary tumor or metastatic lesion) not older than 3 years at time of ICF signature. Quality (at least 20-30% of tumor cells) and quantity (sample size surface area > 5mm2 and > 90um depth) of the tumor sample have to be confirmed mandatorily within 7 days by a central pathological review before confirmation of inclusion. - Patient's disease which is not susceptible to progress during the next 45 days following the ICF signature. - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1. - Adequate organ and marrow function based on a medical records (within 21 days before randomization) as defined below : - Hemoglobin = 9.0 g/dL - Absolute neutrophil count (ANC) = 1.5 x 109/L - Platelets = 100 x 109/L - Lymphocyte count = 1 x 109/L - Serum creatinine CL > 50 mL/min per 1.73m2 using MDRD or CKD-EPI - AST and ALT = 2.5 Upper Limit Normal (ULN) (up to 5 ULN may be tolerated in case of liver metastases) - Serum bilirubin = 1. 5 ULN (in the absence of Gilbert's syndrome). - Patient should understand, sign, and date the written ICF prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. - Patient must be covered by a medical insurance. Exclusion Criteria: - Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication. - Any clinically significant and/or uncontrolled medical disease that could compromise the patient's ability to tolerate an anti-cancer treatment and its procedures (these conditions include but are not limited to severely impaired lung function, active gastrointestinal tract ulceration, acute or chronic uncontrolled liver disease/or severe renal disease, uncontrolled diabetes, history of HIV infection/or active viral infection (HBV, HCV), history of organ allograft or patient taking immunosuppressive treatment). - Patient with the following advanced cancers : - Cancer bearing one of the oncogenic driver mutation: Colorectal cancer : KRAS, NRAS, HRAS and BRAF/Lung cancer: ALK, EGFR, ROS or MET/Breast cancers : RH+ and/or HER2+ - High-grade serous ovarian cancers platinum-sensitive, - Liposarcoma. - Melanoma: BRAF - Patient with non assessable tumor sample. - Patient already included in this study for a type of cancer, can't be included a second time for the same cancer or for any other type of cancer. - Pregnant or breastfeeding woman |
Country | Name | City | State |
---|---|---|---|
France | Institut Bergonié | Bordeaux | |
France | Centre Jean PERRIN | Clermont-Ferrand | |
France | Centre Georges François LECLERC | Dijon | |
France | Centre Oscar Lambret | Lille | |
France | Centre Léon Bérard | Lyon | |
France | Hôpital Privé Jean Mermoz | Lyon | |
France | AP-HM MARSEILLE - Hôpital Nord | Marseille | |
France | Institut Paoli Calmettes | Marseille | |
France | Institut cancer Montpellier - ICM | Montpellier | |
France | Hopital Tenon | Paris | |
France | Institut Curie | Paris | |
France | Centre Eugène Marquis | Rennes | |
France | ICO site René Gauducheau | Saint-Herblain | |
France | Institut de Cancérologie Lucien NEUWIRTH | Saint-Priest-en-Jarez | |
France | Institut Claudius Regaud | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Centre Leon Berard | Roche Pharma AG |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare the proportion of patients for whom a genomically identified recommended therapy could be initiated using the large NGS panel from FoundationOne versus the limited CONTROL panel. | 28 months | ||
Secondary | Compare in the 2 randomization arms the number of patients with at least one actionable alteration. | 28 months | ||
Secondary | Compare in the 2 randomization arms the proportion of patients for which a genomically identified recommended therapy is effectively initiated. | 28 months | ||
Secondary | Describe in both arms the number of patients for whom a genomically identified recommended therapy was available but not initiated. | 28 months | ||
Secondary | Evaluate proportion of patients who could have been initiated a recommended therapy considering only the INCa panel. | Evaluate proportion of patients with at least one actionable alteration and for whom a genomically identified recommended therapy could have been initiated considering only the INCa panel with only 16 cancer-related genes already included in CONTROL panel | 28 months | |
Secondary | Progression-Free Survival (PFS) | Measured from the date of study drugs start to the date of the first objective radiological disease progression using RECIST 1.1 or death. | 24 months | |
Secondary | Overall response Rate (ORR) | the most clinically favorable response recorded from the start of a recommended therapy until the end of treatment, according to RECIST 1.1 | 24 months | |
Secondary | Duration of response (DoR) | Calculated from date of first documented objective response (i.e., Complete Response or Partial Response) until date of first documented progression disease (measurements according to RECIST 1.1 criteria). | 24 months | |
Secondary | Patient Quality Of Life | Measured by the questionnaire EuroQoL-5Dimension-3L | 12 months | |
Secondary | Perform a health economic evaluation | A Cost-Effectiveness and a Cost-utility Analyses comparing the two molecular profiling strategies. | 12 months | |
Secondary | Perform a health economic evaluation | A budget impact analysis to estimate the financial consequences of adoption and diffusion of the large FondationOne panel. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 |